Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 ...

Investor Relations August 1, 2023 This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including Q2-2023 non-GAAP gross margin, non-GAAP operating expense, nonGAAP EBITDA, and non-GAAP earnings per share, 2017 and Q2-2023 liquidity and 2017 and Q2-2023 net debt/EBITDA, guidance with respect to 2023 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and Q2-2023 non-GAAP financial measures to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNIC ...

Omnicell, Inc. (NASDAQ:OMCL) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Kathleen Nemeth - Head of IR Randall Lipps - Chief Executive Officer Nchacha Etta - EVP and Chief Financial Officer Conference Call Participants Scott Schoenhaus - KeyBanc Allen Lutz - Bank of America Stan Berenshteyn - Wells Fargo Matt Hewitt - Craig Hallum Capital Group Bill Sutherland - the Benchmark Company David Larsen - BTIG Jessica Tassan - Piper Sandler Operator Good afternoon and welcome eve ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2023 were $291 million, a decrease of $7 million or down 2% from the prior quarter and a decrease of $28 million or down 9% year-over-year [57] - Non-GAAP EBITDA for Q1 2023 was $27 million, an increase of $1 million compared to the previous quarter but a decrease of $24 million year-over-year [66] - Non-GAAP earnings per share for Q1 2023 were $0.39, compared to $0.33 in the prior quarter and $0.83 in the same period last year [66] Business Line Data and Key Metrics Changes - Services revenues for Q1 2023 were $105 million, an increase of 12% over Q1 2022, indicating successful digital transformation efforts [58] - The specialty pharmacy service continues to gain traction, with new partnerships established in Q1 2023, including a major Illinois health system and a Texas-based medical center [46] Market Data and Key Metrics Changes - The healthcare industry is facing ongoing labor constraints and capital budget challenges, which are expected to persist throughout 2023 [11] - Despite these challenges, there is a noted stabilization in the market, with health systems increasingly recognizing the need for automated medication management solutions [35][39] Company Strategy and Development Direction - The company is focused on integrating recent acquisitions to enhance its advanced services offerings, including ReCept, FDS Amplicare, and MarkeTouch Media [37] - A strategic alliance with Long Island University was announced to open the Center for Innovative Medication Management, aimed at fostering pharmacy education and technology [48][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic uncertainties while executing its growth strategy [18][55] - The company anticipates a sequential revenue growth from the first half to the second half of 2023, supported by a healthy backlog [70] Other Important Information - The company is undergoing a search for a new CFO as the current CFO is set to step down [28] - The company published its 2022 ESG report, highlighting efforts to protect patient data and foster a culture of inclusivity [27] Q&A Session Summary Question: Can you provide updates on the Specialty Services pipeline and the 340B opportunity? - Management indicated strong growth in the pipeline for Specialty Services, particularly in response to health systems' needs for specialty pharmacy operations [12] Question: What is the expectation for inflation trends in 2023? - Management expects pricing impacts to exceed inflation, with sufficient semiconductor inventory to cover most of the year [64][65] Question: How is the backlog trending as we approach midyear? - Management noted that the backlog remains healthy, with significant revenue expected to come from it [71] Question: What part of EnlivenHealth is resonating most with retail pharmacies? - The focus is on patient engagement and chronic care management, with retail pharmacies seeking better solutions for revenue cycle management [52][53] Question: What is the outlook for the point-of-care XT product line? - Management expects a stable continuation of the upgrade cycle for the XT series, despite some choppiness during the pandemic [97]

Omnicell, Inc. (NASDAQ:OMCL) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President and CEO Scott Seidelmann - Executive Vice President and CCO Peter Kuipers - Executive Vice President and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Matt Hewitt - Craig-Hallum Capital Group Scott Schoenhaus - KeyBanc Jessica Tassan - Piper Sandler Bill Sutherland ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL, INC. (Exact name of regis ...

Omnicell, Inc. (NASDAQ:OMCL) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Jessica Tassan - Piper Sandler Allen Lutz - Bank of Am ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL ...